Analysis of the Efficacy of Polyenyl Phosphatidylcholine in Combination with Liraglutide in Nonalcoholic Fatty Liver Disease and the Effect of Omentin-1 and Vaspin Expression.

Jin Y, Liu T, Tong Z, Dong M

Alternative therapies in health and medicine1 Jul 2025Cited by 2 (Europe PMC)

PMID38814610PepBankPUB-38814610

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with NAFLD, PPC plus liraglutide had a higher clinical effectiveness rate than PPC alone (95.00% versus 83.33%; P < .05).
In plain wordsIn people with fatty liver disease, PPC plus liraglutide had a higher effectiveness rate than PPC alone.
Peptide
Liraglutide
Outcome
IncreaseClinical effectiveness rate
Study
n = 120
Comparator
PPC alone
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Clinical effectiveness rate
95%
PPC plus liraglutide; P < .05 versus PPC alone
Clinical effectiveness rate
83.33%
PPC alone
Source sentences
Summary
In the observation group, the clinical effectiveness rate (95.00%) was significantly higher than that in the control group (83.33%) (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
Report a problemFND-3881461001
02HumanRandomized controlled trialEfficacy outcome
In patients with NAFLD, PPC plus liraglutide produced lower vaspin levels than PPC alone after treatment (P < .05).
In plain wordsIn people with fatty liver disease, PPC plus liraglutide led to lower vaspin levels than PPC alone.
Peptide
Liraglutide
Outcome
DecreaseVaspin
Study
n = 120
Comparator
PPC alone
Outcome group
Adipokines · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, levels of vaspin, FGF21, ALT, AST, and GGT were lower in the observation group compared to the control group, while omentin-1 levels were higher (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
Report a problemFND-3881461002
03HumanRandomized controlled trialEfficacy outcome
In patients with NAFLD, PPC plus liraglutide produced lower FGF21 levels than PPC alone after treatment (P < .05).
In plain wordsIn people with fatty liver disease, PPC plus liraglutide led to lower FGF21 levels than PPC alone.
Peptide
Liraglutide
Outcome
DecreaseFGF21
Study
n = 120
Comparator
PPC alone
Outcome group
Adipokines · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, levels of vaspin, FGF21, ALT, AST, and GGT were lower in the observation group compared to the control group, while omentin-1 levels were higher (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
Report a problemFND-3881461003
04HumanRandomized controlled trialEfficacy outcome
In patients with NAFLD, PPC plus liraglutide produced lower ALT levels than PPC alone after treatment (P < .05).
In plain wordsIn people with fatty liver disease, PPC plus liraglutide led to lower ALT than PPC alone.
Peptide
Liraglutide
Outcome
DecreaseALT
Study
n = 120
Comparator
PPC alone
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, levels of vaspin, FGF21, ALT, AST, and GGT were lower in the observation group compared to the control group, while omentin-1 levels were higher (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
Report a problemFND-3881461004
05HumanRandomized controlled trialEfficacy outcome
In patients with NAFLD, PPC plus liraglutide produced lower AST levels than PPC alone after treatment (P < .05).
In plain wordsIn people with fatty liver disease, PPC plus liraglutide led to lower AST than PPC alone.
Peptide
Liraglutide
Outcome
DecreaseAST
Study
n = 120
Comparator
PPC alone
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, levels of vaspin, FGF21, ALT, AST, and GGT were lower in the observation group compared to the control group, while omentin-1 levels were higher (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
Report a problemFND-3881461005
06HumanRandomized controlled trialEfficacy outcome
In patients with NAFLD, PPC plus liraglutide produced lower GGT levels than PPC alone after treatment (P < .05).
In plain wordsIn people with fatty liver disease, PPC plus liraglutide led to lower GGT than PPC alone.
Peptide
Liraglutide
Outcome
DecreaseGGT
Study
n = 120
Comparator
PPC alone
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, levels of vaspin, FGF21, ALT, AST, and GGT were lower in the observation group compared to the control group, while omentin-1 levels were higher (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
Report a problemFND-3881461006
07HumanRandomized controlled trialEfficacy outcome
In patients with NAFLD, PPC plus liraglutide produced higher omentin-1 levels than PPC alone after treatment (P < .05).
In plain wordsIn people with fatty liver disease, PPC plus liraglutide led to higher omentin-1 levels than PPC alone.
Peptide
Liraglutide
Outcome
IncreaseOmentin-1
Study
n = 120
Comparator
PPC alone
Outcome group
Adipokines · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, levels of vaspin, FGF21, ALT, AST, and GGT were lower in the observation group compared to the control group, while omentin-1 levels were higher (P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
Report a problemFND-3881461007
08HumanRandomized controlled trialSafety outcome
In patients with NAFLD, adverse reaction rates did not differ significantly between PPC plus liraglutide and PPC alone (10.00% versus 6.67%; P > .05).
In plain wordsIn people with fatty liver disease, adverse reaction rates were similar with PPC plus liraglutide and PPC alone.
Peptide
Liraglutide
Outcome
No significant changeAdverse reaction rate
Study
n = 120
Comparator
PPC alone
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Adverse reaction rate
10%
PPC plus liraglutide; P > .05 versus PPC alone
Adverse reaction rate
6.67%
PPC alone
Source sentences
Summary
Adverse reaction rates did not significantly differ between the two groups (10.00% vs. 6.67%) (P > .05).
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
Report a problemFND-3881461008

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

09HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In patients with NAFLD, vaspin levels decreased after treatment in both PPC alone and PPC plus liraglutide groups.
In plain wordsIn people with fatty liver disease, vaspin decreased in both PPC-alone and PPC-plus-liraglutide groups.
Peptide
Liraglutide
Outcome
DecreaseVaspin
Study
n = 120
Outcome group
Adipokines · Metabolic and weight
Source sentences
Summary
After treatment, both groups showed decreased levels of vaspin, FGF21, ALT, AST, and GGT, along with increased omentin-1 levels.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3881461009
10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In patients with NAFLD, FGF21 levels decreased after treatment in both PPC alone and PPC plus liraglutide groups.
In plain wordsIn people with fatty liver disease, FGF21 decreased in both PPC-alone and PPC-plus-liraglutide groups.
Peptide
Liraglutide
Outcome
DecreaseFGF21
Study
n = 120
Outcome group
Adipokines · Metabolic and weight
Source sentences
Summary
After treatment, both groups showed decreased levels of vaspin, FGF21, ALT, AST, and GGT, along with increased omentin-1 levels.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3881461010
11HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In patients with NAFLD, ALT decreased after treatment in both PPC alone and PPC plus liraglutide groups.
In plain wordsIn people with fatty liver disease, ALT decreased in both PPC-alone and PPC-plus-liraglutide groups.
Peptide
Liraglutide
Outcome
DecreaseALT
Study
n = 120
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
After treatment, both groups showed decreased levels of vaspin, FGF21, ALT, AST, and GGT, along with increased omentin-1 levels.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3881461011
12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In patients with NAFLD, AST decreased after treatment in both PPC alone and PPC plus liraglutide groups.
In plain wordsIn people with fatty liver disease, AST decreased in both PPC-alone and PPC-plus-liraglutide groups.
Peptide
Liraglutide
Outcome
DecreaseAST
Study
n = 120
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
After treatment, both groups showed decreased levels of vaspin, FGF21, ALT, AST, and GGT, along with increased omentin-1 levels.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3881461012
13HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In patients with NAFLD, GGT decreased after treatment in both PPC alone and PPC plus liraglutide groups.
In plain wordsIn people with fatty liver disease, GGT decreased in both PPC-alone and PPC-plus-liraglutide groups.
Peptide
Liraglutide
Outcome
DecreaseGGT
Study
n = 120
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
After treatment, both groups showed decreased levels of vaspin, FGF21, ALT, AST, and GGT, along with increased omentin-1 levels.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3881461013
14HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In patients with NAFLD, omentin-1 levels increased after treatment in both PPC alone and PPC plus liraglutide groups.
In plain wordsIn people with fatty liver disease, omentin-1 increased in both PPC-alone and PPC-plus-liraglutide groups.
Peptide
Liraglutide
Outcome
IncreaseOmentin-1
Study
n = 120
Outcome group
Adipokines · Metabolic and weight
Source sentences
Summary
After treatment, both groups showed decreased levels of vaspin, FGF21, ALT, AST, and GGT, along with increased omentin-1 levels.
3 context sentences(design, population, supporting numbers)
Summary · context
One hundred twenty NAFLD patients were randomly assigned to either the observation group (n = 60) or the control group (n = 60).
Summary · context
The control group received single-dose PPC treatment, while the observation group received a combination of PPC and liraglutide for 12 weeks.
Summary · context
Clinical efficacy, adipose-related factors (omentin-1, vaspin, serum fibroblast growth factor 21 (FGF21)), liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)), and adverse reaction rates were compared between the two groups before and after treatment.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3881461014

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.